EP0053893A1 - Dérivés de l'acide clavulanique, leur préparation et leur application - Google Patents

Dérivés de l'acide clavulanique, leur préparation et leur application Download PDF

Info

Publication number
EP0053893A1
EP0053893A1 EP81305564A EP81305564A EP0053893A1 EP 0053893 A1 EP0053893 A1 EP 0053893A1 EP 81305564 A EP81305564 A EP 81305564A EP 81305564 A EP81305564 A EP 81305564A EP 0053893 A1 EP0053893 A1 EP 0053893A1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
ester
salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP81305564A
Other languages
German (de)
English (en)
Other versions
EP0053893B1 (fr
Inventor
John Barry Harbridge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Publication of EP0053893A1 publication Critical patent/EP0053893A1/fr
Application granted granted Critical
Publication of EP0053893B1 publication Critical patent/EP0053893B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1896—Compounds having one or more Si-O-acyl linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to derivatives of clavulanic acid and in particular to 9-N-tetrazolyldeoxyclavulanate derivatives. These are of use as antibiotics and as ⁇ -lactamase inhibitors.
  • the present invention relates to compounds wherein the hydroxy group at C-9 position is replaced by a tetrazole group.
  • the present invention provides a compound of formula (II) or a salt or ester thereof: wherein X is an optionally substituted tetrazolyl group attached via a nitrogen atom.
  • X represents a group of sub-formula (i): wherein R is hydrogen; esterified or salified carboxy, optionally substituted C l-6 alkoxy, C 1-6 alkyl, C 2-6 alkenyl, or aryl; azido,isocyano, cyano, nitro, bromo, chloro, or is a group of the sub-formula (a): wherein n is zero or one; R 1 is hydrogen or optionally substituted C 1-6 alkyl, C 1-6 alkanoyl, or arylcarbonyl; and R is hydrogen, C 1-6 alkyl or C 1-6 alkanoyl; or R and R may be joined to form with the nitrogen atom to which they are attached, an optionally substituted 4,5 or 6- membered ring.
  • R is hydrogen; esterified or salified carboxy, optionally substituted C l-6 alkoxy, C 1-6 alkyl, C 2-6 alkenyl, or aryl; azido,isocyan
  • X represents a group of sub-formula (i) : wherein R is hydrogen; optionally substituted C 1-6 alkoxy, C 1-6 alkyl, C 2-6 alkenyl, or aryl; azido, isocyano, cyano, nitro, bromo, chloro, or is a group of the sub-formula (aa): wherein R 1 is hydrogen or optionally substituted C 1-6 alkyl, C l-6 alkanoyl, or arylcarbonyl; and R 2 is hydrogen, C 1-6 alkyl or C 1-6 alkanoyl; or R 1 and R 2 may be joined to form with the nitrogen atom to which they are attached, an optionally substituted 4,5 or 6-membered ring.
  • R is hydrogen; optionally substituted C 1-6 alkoxy, C 1-6 alkyl, C 2-6 alkenyl, or aryl; azido, isocyano, cyano, nitro, bromo, chloro, or is a group
  • the compounds of the formula (II) may be presented in the form of the carboxylic acid at the C-3 position.
  • the compounds of the formula (II) may be in the form of a pharmaceutically acceptable salt.
  • Suitable pharmaceutically acceptable salts of the compounds of formula (II) include metal salts, for example aluminium, alkali metal salts such as sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy-lower alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylamine, N,N-dibenzylethylenediamine, 1-ephenamine, N-ethylpiperidine, N-benzyl-S-phenethyl
  • the compounds of the formula (II) alternatively may be provided as in vivo hydrolysable esters.
  • Such esters are those which hydrolyse in the human body to produce the parent acid or salt thereof.
  • Suitable in vivo hydrolysable esters include those of the sub-formulae (b) and (c) : wherein R 3 is a hydrogen atom or a methyl or phenyl group; R 4 is C 1-6 alkyl, phenyl, phenyl (C l-3 ) alkyl, C 1-6 alkoxy, phenoxy, phenyl (C 1-3 ) alkoxy; or Rand R 4 are joined to form a 1,2-diphenylene or 4,5-dimethoxy-1,2-diphenylene group: R 5 is a divalent methylene or ethylene radical, R 6 and R 7 are independently methyl or ethyl groups.
  • R 3 is a hydrogen atom.
  • R 4 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, phenyl, benzyl, methoxy, ethoxy, n-propyloxy and isopropyloxy.
  • R4 is tert-butyl.
  • R 3 and R 4 are joined so that the ester is a phthalidyl or 3,4-dimethoxyphthalidyl ester.
  • esters are the acetoxymethyl, a-ethoxycarbonyloxyethyl, pivaloyloxymethyl and phthalidyl esters, of which the phthalidyl is favoured.
  • the in vivo hydrolysable nature of the ester may be confirmed by administration to an animal such as a mouse or rat and determination of the presence of a compound of the formula (II) or salt thereof in the body fluids of the animal, for example the blood or urine. Alternatively hydrolysis in human blood or serum may be determined.
  • group R may be optionally substituted by one or more groups or atoms selected from hydroxy, halo, aryl, carboxy, C 1-6 alkanoyl, C 1-6 alkano y loxy, C 1-6 alkoxy, C 1-6 alkoxycarbonyl, aryl (C 1-6 ) alkoxy, arylcarbonyl, C l-6 alkylthio, arylthio, amino, azido,C 1-6 alkylamino or di(C 1-6 ) alkylamino.
  • groups or atoms selected from hydroxy, halo, aryl, carboxy, C 1-6 alkanoyl, C 1-6 alkano y loxy, C 1-6 alkoxy, C 1-6 alkoxycarbonyl, aryl (C 1-6 ) alkoxy, arylcarbonyl, C l-6 alkylthio, arylthio, amino, azido,C 1-6 alkylamino or di(C 1-6 )
  • R when it is not methyl may optionally be substituted by one or more groups selected from hydroxy, halo, carboxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, C 1-6 alkoxy, C 1-6 alkoxycarbonyl, C 1-10 aralkox y , arylcarbonyl, C 1-6 alkylthio, arylthio, amino, C 1-6 alkylamino or di(C 1-6 ) alkylamino.
  • R 2 when it is not methyl may optionally be substituted by one or more groups selected from hydroxy, halo, carboxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, C 1-6 alkoxy, C 1-6 alkoxycarbonyl, aryl (C 1-6 ) alkoxy, arylcarbonyl, C 1-6 alkylthio, arylthio, amino, C 1-6 alkylamino or di(Cl-6 alkylamino.
  • R 1 is methyl suitably it may optionally be substituted by carboxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy,C 1-6 alkoxycarbonyl or arylcarbonyl.
  • R 2 is methyl suitably it may optionally be substituted by carboxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy,C 1-6 alkoxycarbonyl or arylcarbonyl.
  • aryl includes phenyl, pyrrolyl, furyl, thienyl, indolyl, benzofuryl, thionaphthyl, and any of such groups being optionally substituted.
  • R is a hydrogen atom.
  • R is a C 1-6 alkyl, C 2-6 alkenyl, C 1-10 aralkyl or aryl group, any of such groups being optionally substituted. More suitably R is methyl, ethyl,t-butyl, phenyl, benzyl or carboxymethyl.
  • R is salified carboxy, the carboxy group is salified with a pharmaceutically acceptable salt, suitable salts being as described in relation to the C-3 carboxy.
  • the esterifying group is an in vivo hydrolysable ester of sub-formula (b) or (c) as hereinbefore defined, or alternatively an ester of the sub-formulae (d) or (e): wherein A 1 is C 1-6 alkyl optionally substituted by C 1-7 alkoxy; A is C 2-5 alkenyl optionally substituted by phenyl or is a phenyl group optionally substituted by one or more atoms or groups selected from fluorine, chlorine, bromine, nitro, C 1-4 alkyl or C 1-4 alkoxy; and A3 is hydrogen, C 1-4 alkyl or a phenyl group optionally substituted by fluorine, chlorine, bromine, nitro, C 1-4 alkyl or C 1-4 alkoxy.
  • a 1 is a Cl-6alkyl group such as methyl or propyl; or CHA 2
  • a 3 is a benzyl or substituted benzyl group
  • R is a group of the sub-formula -CONR1R2 as hereinbefore defined. More suitably R 1 is a hydrogen atom or optionally substituted C 1-6 alkyl group. More suitably R 2 is a hydrogen atom.
  • R is a group of sub-formula -NR 1 R 2 as hereinbefore defined.
  • R 1 is a hydrogen atom, C 1-6 alkyl, C 1-6 alkanoyl or C 1-10 aralkanoyl, any of such groups being optionally substituted.
  • R 2 is a hydrogen atom.
  • R 1 is a hydrogen atom or a C 1-6 alkanoyl group such as acetyl.
  • This invention extends to the compounds of the formula (II) in both the structural forms (III) and (IV):
  • C-9 substituent is either a tetrazol-1-yl or tetrazol-2-yl group.
  • the present invention also provides a pharmaceutical composition which comprises a compound of the formula (II) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof and a pharmaceutically acceptable carrier.
  • compositions of the invention include those in a form adapted for oral, topical or parenteral use and may be used for the treatment of the infection in animals, particularly in mammals including humans.
  • compositions of this invention include tablets, capsules, creams, syrups, suspensions, solutions, reconstitutable powders and sterile forms suitable for injection or infusion.
  • Such compositions may contain conventional pharmaceutically acceptable materials such as diluents, binders, colours, flavours, preservatives, disintegrant and the like in accordance with conventional pharmaceutical practice in the manner well understood by those skilled in the art of formulating antibiotics.
  • compositions of a compound of the invention are particularly suitable as high blood levels of the compound can occur after administration by injection or infusion.
  • one preferred composition aspect of this invention comprises a compound of the invention in sterile form and most suitably in sterile crystalline form.
  • the injectable solution of the compound of this invention may be made up in a sterile pyrogen-free liquid such as water, aqueous ethanol or the like.
  • An alternative approach to administering the compounds of this invention is to utilise an injectable suspension.
  • Such suspensions may be made up in sterile water; sterile saline or the like and may also contain suspending agents such as polyvinylpyrrolidone, lecithin or the like Alternatively such compositions may be prepared in an acceptable oil suspending agent such as arachis oil or its equivalent.
  • an acceptable oil suspending agent such as arachis oil or its equivalent.
  • the compounds of this invention should be in the form of fine particles.
  • Unit dose compositions comprising a compound of this invention adapted for oral administration form a further suitable composition aspect of this invention.
  • Unit dose compositions comprising a compound of this invention adapted for topical administration are also presented by this invention.
  • 'topical administration' also includes local administration to internal surfaces of mammary glands of cattle, for example during the treatment of mastitis by intra-mammary administration.
  • the compound of the formula may be present in the composition as sole therapeutic agent or it may be present together with other therapeutic agents such as a penicillin or cephalosporin.
  • a penicillin or cephalosporin which shows instability to ⁇ -lactamases since the resulting composition shows enhanced effectiveness (synergy).
  • Suitable penicillins cephalosporins or other ⁇ -lactam antibiotic for inclusion in such synergistic compositions include not only those known to be highly susceptible to ⁇ -lactamases but also those which have a degree of intrinsic resistance to P-lactamases.
  • Suitable penicillins for inclusion in the compositions of this invention include benzylpenicillin, phenoxymethylpenicillin, carbenicillin, azidocillin, propicillin, ampicillin, amoxycillin, epicillin, ticarcillin, cyclacillin, pirbenicillin, azlocillin, mezlocillin, sulbenicillin, piperacillin, and other known penicillins including pro-drugs therefor such as their in vivo hydrolysable esters such as the acetoxymethyl, pivaloyloxymethyl, a-ethoxycarbonyloxyethyl or phthalidyl esters of ampicillin, benzylpenicillin or amoxycillin, and aldehyde or ketone adducts of penicillins containing a 6-a-aminoacetamide side chain (such as hetacillin, metampicillin and analogous derivatives of amoxycillin) or a-esters of carbenicillin or ticarcillin
  • Suitable cephalosporins for inclusion in the compositions of this invention include cefatrizine, cephaloridine, cephalothin, cefazolin, cephalexin, cephacetrile, cephamandole nafate, cephapirin, cephradine, 4-hydroxycephalexin, cefaparole, cepha- loglycin, cefoperazone, and other known cephalosporins or prodrugs therefor.
  • Such compounds are frequently used in the form of a salt or hydrate of the like.
  • the composition will be adapted for parenteral administration.
  • Such penicillins may be used as a pharmaceutically acceptable salt such as the sodium salt.
  • the ampicillin or amoxycillin may be used in the form of fine particles of the zwitterionic form (generally as ampicillin trihydrate or amoxycillin trihydrate) for use in an injectable suspension, for example, in the manner hereinbefore described for a compound of this invention.
  • the preferred penicillin for use in the synergistic composition is amoxycillin, for example as its sodium salt or trihydrate.
  • the ratio of a compound of the invention to the penicillin or cephalosporin agent may vary over a wide range of ratios, such as from 10:1 to 1:15 for example 1 - 0:1 to 1:10 such as about 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5 or 1:6 (wt/wt, based on pure free antibiotic equivalent).
  • the total quantity of a compound of.the invention in any unit dosage form will normally be between 25 and 1000 mg and will usually be between 50 and 500 mg, for example about 62.5, 100, 125, 150, 200 or 250 mg.
  • compositions of this invention may be used for the treatment of infections of inter alia, the respiratory tract, the urinary tract and soft tissues in humans and mastitis in cattle.
  • the compounds of the invention will be administered each day of treatment but more usually between 100 and 1000 mg of the compounds of the invention will be adminstered per day, for example at 1-6 doses, more usually as 2, 3 or 4 doses. However for the treatment of more severe systemic infections or infections of particularly intransigent organisms higher doses may be used in accordance with clinical practice.
  • the penicillin or cephalosporin in the synergistic composition of this invention will normally be present at approximately the amount at which it is conventionally used which will usually be expected to be from about 62.5 to 3000 mg per dose, more usually about 125, 250, 500 or 1000 mg per dose.
  • composition of this invention will contain from 150 to 1000 mg of amoxycillin as the trihydrate or sodium salt and from 25 to 500 mg of a compound of this invention.
  • composition of this invention will contain from 150 to 1000 mg of ampicillin or a pro-drug therefor and from 25 to 500 mg of a compound of this invention.
  • this form of composition will contain ampicillin trihydrate, ampicillin anhydrate, sodium ampicillin, hetacillin, pivampicillinhydro- chloride, bacampicillin hydrochloride, or talampicillin hydrochloride. Most suitably this form of the composition will contain a compound of the formula ( II ) when in crystalline form.
  • the preceding composition will contain from 200 to 700 mg of the penicillin component. Most suitably the preceding composition will comprise from 50 to 250 mg of a compound of the formula (II) preferably in crystalline form.
  • compositions may be adapted for oral or parenteral use except when containing an in vivo hydrolysable ester of ampicillin or amoxycillin in which case the compositions will not be adapted for parenteral administration.
  • composition of this invention will contain from 200 to 2000 mg of carbenicillin, ticarcillin or a pro-drug therefore and from 50 to 500 mg of a compound of the invention.
  • this form of composition will contain di-sodium carbenicillin.
  • this form of the composition will contain di-sodium ticarcillin.
  • this form of the composition will contain from 75 to 250 mg of a compound of the formula (II) preferably in crystalline form.
  • Such compositions containing di-salts of carbenicillin and ticarcillin will be adapted for parenteral administration.
  • the present invention also provides a method of treating bacterial infections in animals, particularly humans or domestic mammals, which comprises the administration of a composition of this invention.
  • the infection treated will be due to a strain of Staphylococcus aureus, Klebsiella aerogenes, Escherichia coli, Proteus sp., Bacteroides fragilis or the like.
  • the organisms believed to be most readily treated by an antibacterially effective amount of a compound of this invention is Staphylococcus aureus.
  • the other organisms named are more readily treated by using a synergistically effective amount of the compound of the invention and a penicillin or cephalosporin.
  • the administration of the two components may take place separately but in general we prefer to use a composition containing both the synergist and the penicillin or cephalosporin.
  • the indications for treatment include respiratory tract and urinary tract infections in humans and mastitis in cattle.
  • the present invention provides a process for the preparation of a compound of the formula (II) or a salt or ester thereof which proces$ comprises the reaction of a compound of the formula (V): wherein R 8 is an esterifying group, with::
  • Suitable compounds of the formula (VII) include those wherein R 9 and R 10 are independently selected from methyl, ethyl, propyl, butyl, phenyl and benzyl groups. It is generally convenient that R 9 and R 10 represent the same moiety. Particularly suitable compounds of the formula (VII) include those wherein R 9 and R 10 each represent a methyl, ethyl, t-butyl or iso-propyl group.
  • the compound of the formula (VII) may be replaced by a stabilised diazoalkane, such as diphenyldiazomethane or ethyl diazoacetate. This aspect is not preferred when the compound of the formula (VI) is strongly acidic.
  • Suitable compounds of the formula (VIII) include those wherein the R , R 12 and R 13 groups are selected from methyl, ethyl, n-propyl, n-butyl, benzyl, phenyl and methoxyphenyl groups. It is generally convenient that R 11 , R 12 and R 13 each represent the same moiety.
  • Favoured compounds of the formula (VIII) include tri-aryl p hosphines and tri-alkylphosphites. Particularly suitable compounds of the formula (VIII) include triphenylphosphine, trimethylphosphite, tri-ethylphosphite, tri-p-methoxyphenylphosphine and tri-n-butylphosphine.
  • ester of clavulanic acid may be used in this reaction (ie the compound of the formula (V) but in general it is most suitable to use an in-vivo hydrolysable ester of sub-formulae (b) or (c) as hereinbefore defined, or alternatively an ester of sub-formulae (d) or (e) may be used as such esters are readily converted to the parent acid or its salt by methods appropriate to the particular ester, for example basic hydrolysis, enzymatically-catalysed hydrolysis hydrogenolysis., electrolysis or photolysis.
  • A is C 1-6 alkyl optionally substituted by C 1-7 alkoxy
  • a 2 is C 2-5 alkenyl optionally substituted by phenyl or is a phenyl group optionally substituted by one or more atoms or groups selected from fluorine, chlorine, bromine, nitro, C 1-4 alkyl or CI-4 alkoxy
  • A3 is hydrogen, C 1-4 alkyl or a phenyl group optionally substituted by fluorine, chlorine, bromine, nitro, C 1-4 alkyl or C l-4 alkoxy.
  • ester-forming groups are those which may also be removed under conventional conditions by methods appropriate to the particular ester, for example basic hydrolysis, enzymatically-catalysed hydrolysis or hydrogenolysis, for example benzoylmethyl, pyridylmethyl, 2,2,2-trichloroethyl, 2,2,2-tribromoethyl, triphenylmethyl, 2-benzyloxyphenyl, 4-methoxycarbonylbenzyl, 4-methylthiophenyl, or a silyl, stannyl or pentavalent phosphorus-containing group.
  • ester for example basic hydrolysis, enzymatically-catalysed hydrolysis or hydrogenolysis, for example benzoylmethyl, pyridylmethyl, 2,2,2-trichloroethyl, 2,2,2-tribromoethyl, triphenylmethyl, 2-benzyloxyphenyl, 4-methoxycarbonylbenzyl, 4-methylthiophenyl, or a silyl,
  • esters of clavulanic acid for use in this process include methoxymethyl clavulanate, benzyl clavulanate, p-nitrobenzyl clavulanate, p-methoxybenzyl clavulanate, methyl clavulanate, and silyl esters such as tri-(C 1-6 )alkylsilyl clavulanates and di-(C 1-6 )alkyl-phenyl silyl clavulanates, for example tri-isopropylsilyl clavulanate and di-tert-butyl-phenyl silyl clavulanate.
  • the reaction is performed in an inert organic solvent.
  • the solvent used should be aprotic and substantially unreactive towards the reagents involved. Suitable solvents include tetrahydrofuran, dioxan, ethyl acetate, benzene, toluene and chlorobenzene. Of these tetrahydrofuran is preferred. On occasion it is necessary to have a small proportion of dimethylformamide in the reaction solvent to aid solubility of the compound of the formula (VI).
  • the reaction is normally carried out at a non-extreme temperature such as -20°C to +100 C, more usually from about 5°C to 50°C and conveniently at ambient temperature (approximately 15 0 C to 25 0 C).
  • a non-extreme temperature such as -20°C to +100 C, more usually from about 5°C to 50°C and conveniently at ambient temperature (approximately 15 0 C to 25 0 C).
  • de-esterfication may be performed in conventional manner to afford the carboxylic acid or salt thereof.
  • the lithium salts of the compounds of the formula (II) may be formed first and then converted to a different salt, for example by ion-exchange.
  • the salts and free acids of the compounds of the formula (II) may be converted to esters of the compounds of the formula (II) in conventional manner, for example by reaction with one equivalent of a reactive halide in a solvent such as dimethylformamide.
  • a compound of the formula (II) wherein R is esterified carboxy may be converted into a compound of the formula (II) wherein R is salified carboxy in conventional manner, for example, the methods for de-esterification of the C-3 ester of clavulanic acid may be used where appropriate, in particular basic hydrolysis of alkyl esters is useful.
  • Conversion of a compound of the formula (II) wherein R is salified carboxy to a compound of the formula (II) wherein R is hydrogen may be in conventional manner for example by acidification, extraction into orqanic solvent and treatment with aqueous base.
  • the present invention provides a process for the preparation of a compound of the formula ( III ) or salt or ester thereof which process comprises the reaction of azide ion with an ester of a compound of the formula (LX): wherein R is as defined in relation to formula (II) and R 14 is a bromine or chlorine atom, and thereafter if desired:
  • the reaction is suitably performed in an inert organic solvent such as dichloromethane or chloroform.
  • the reaction may be carried out at a non-extreme temperature such as -60°C to +60°C, preferably from -20°C to 40°C, more preferably from 0°C to +30°C and conveniently at ambient temperature.
  • a non-extreme temperature such as -60°C to +60°C, preferably from -20°C to 40°C, more preferably from 0°C to +30°C and conveniently at ambient temperature.
  • the azide ion may be introduced to the reaction as an inorganic azide for example sodium azide, or as an organic azide such as tetramethylguanidinium azide. Care must be exercised when selecting an appropriate azide as many azides, particularly heavy metal azides, are explosive.
  • the compound of the formula (IX) may be prepared by a process which comprises the reaction of a corresponding ester of a compound of the formula (X): wherein R is as defined in relation to formula (II), with an imino-halogenating agent and a base.
  • the solvent used is suitably an inert organic solvent such as dichloromethane, chloroform, carbon tetrachloride, dichloroethane, tetrahydrofuran or dioxan.
  • the reaction is performed in the presence of a base.
  • a base is an organic base for example a tertiary amine such as triethylamine, trimethylamine or N-alkylmorpholine, and pyridine.
  • the organic base is N-methylmorpholine.
  • triphenylphosphine or tri-p-methoxyphenylphosphine with carbon tetrahalide as an imino-halogenating agent, for example triphenylphosphine in carbon tetrachloride or triphenylphosphine and carbon tetrabromide in an organic solvent, for example dichloromethane, chloroform or benzene.
  • the compounds of the formula (X) may be prepared by the methods of Belgian Patent Nos. 860042 and 866496.
  • the present invention provides a process for the preparation of a compound of the formula (XI): on galt or ester thereof wherein R 15 is an esterified or salified carboxy or a group CONR 1 R 2 as hereinbefore defined, which process comprises the reaction of a compound of the formula (XII): wherein R is as hereinbefore defined, with a reactive nitrile of the formula (XIII): and thereafter if necessary:
  • R 15 is a conjugating group, for example an esterified carboxy group of the sub-formula ii): wherein R 16 is an esterifying group.
  • R 16 is an ester of the sub-formulae (b), (c), (d) or (e).
  • R 16 is optionally substituted C 1-6 alkyl or optionally substituted benzyl, for example methyl, ethyl or benzyl.
  • the reaction is performed at a temperature between 0 0 C and 120°C, preferably between 50°C and 100°C.
  • the reaction may be performed in the absence of solvent (if the compound of the formula (XIII) is a liquid) or alternatively in the presence of solvent, suitably an organic solvent.
  • solvent suitably an organic solvent.
  • suitable solvents include inert organic solvents such as tetrahydrofuran and chloroform.
  • the compounds of the formula (XII) may be prepared by the methods of Belgian Patent No. 855,375.
  • reaction mixture was evaporated under reduced pressure to about 70 ml, then re-evaporated with two successive portions of 50 ml of toluene until reduced to a syrup containing crystalline material. 100 ml of toluene was added, cooled to 2-3 0 C, filtered off in- solubles and the filtrate re-evaporated. The mixture was subjected to gradient elution chromatography on silica gel, using a short wide column, eluted with ethyl acetate and n-hexane graded from 1:2 to 2:1 ratio. After an initial fractionation into more polar and less polar products, the latter were combined and rechromatographed on a similar column.
  • This compound may be hydrated.
  • 5-aminotetxazole monohydrate was dehydrated by heating in a Dean and Starke apparatus using toluene to oo-distil the water. When no further water distilled, the suspension was oooled to room temperature, decanted off the toluene, added dry ether and decanted again, finally dried in vacuo over P 2 O 5 : 2 .3 g of this material was dissolved in about 8 ml of warm dry N,N-dimethyl- formsmide.
  • the filtrate was re-evaporated, and subjected to gradient elution chromatography on silica gel using ethyl acetate and cyclohexane mixtures, graded from 1:2 ratio through 2:1 ratio to pure ethyl acetate, as elution aolvent.
  • the most polar ⁇ -lactam-oontaining product (as determined by tlc (Si0 2 ) in 2:1 ethyl acetate - cyclohexane) was collected, and fractions containing it were combined and evaporated, to yield 140 mg of an oil containing some N.N-dimethylformamide. This was not further purified.
  • the partially purified benzyl ester of example 9 (140 mg) was dissolved in redistilled tetrahydrofuran (10 ml) containing water (1 drop) and 10% palladised charcoal (70mg). It was hydrogenated at ambient temperature and pressure for about 1 hour. The catalyst was removed by filtration, washed with water and the filtrate and washings diluted with water and titrated to pH 7.3 with lithium hydroxide solution. The solution was evaporated to near dryness, 1-propanol added and re-evaporated to dryness. The colourless crystalline solid was triturated with acetone filtered off, washed with acetone and dried in vacuo, to yield the title compound (30 mg).
  • Nmr (CD 3 COCD 3 ;CDC1 3 was unsuitable) 6 1.39 (3H,t,J 7Hz, CH 3 CH 2 ), 3.10 (lH,d,J 17Hz, 6- ⁇ -CH), 3.64 (lH,dd,J 17 and 3Hz, 6-a CH), 4.47 (2H,q,J 7Hz, CH 3 CH 2 ), 5.05 (lH,t,J 8Hz, 8-CH ), 5.18 (2H,s, PhCH 2 ), 5.23 (lH,s, 3-CH), 5.44 (2H,d, J 8Hz, 9-CH 2 ) 5.81 (lH,d, J 3Hz, 5-CH) and 7.33 (5H,s, Ph).
  • Nmr (D 2 0) ⁇ 1.33 (3H,t, J 7Hz, CH 3 CH 2 ) 2.12 (acetone) 2.98 (lH,d, J 17Hz, 6- ⁇ -CH) 3.47 (lH,dd, J 17 and 3Hz, 6-a-CH) 4.47 (partially obscured by HOD,q, J 7Hz, CH3CH2), 4.90 (lH,s, 3-CH) 8-CH probably about 5.18, 5.4 (2H,d, J 8Hz, 9-CH 2 ) and 5.66 (lH,d, J 3Hz, 5-CH).
  • Nmr (D 2 0) 6 2.98 (1H,d, J 17Hz, 6- ⁇ -CH), 3.45 (lH,dd, J 17 and 3Hz, 6-a-CH), 4.75-5.4 (5H,m, 3-CH, 9-CH 2 , 8-CH), and 5.63 (lH,d, J 3Hz, 5-CH).
  • the aqueous layer was re-extracted with ethyl acetate, then the solvent layers combined, dried (Na 2 SO 4 ) and evaporated.
  • the residue was subjected to gradient elution chromatography on silica gel, using ethyl acetate and cyclohexane graded from 1 : 1 ratio to neat ethyl acetate as eluents.
  • the product was the most polar ⁇ -lactam-containing component, having an R f (1:1 ethyl acetate-hexane)>0.1.
  • About 50 mg of the pure ester was obtained after evaporation of solvent, though some further fractions contained the compound in a less pure state.
  • the solution was acidified by the addition of pre-washed IR120 (H + ) resin in two portions, decanting each time, to give a pH of 1.5-1.7, then neutralised to pH 7.2 by the addition of IM KOH.
  • Example 18 The procedure of Example 18 was repeated using sodium hydroxide solution in place of lithium hydroxide solution.
  • Example 18 The procedure of Example 18 was repeated using potassium hydroxide solution in place of lithium hydroxide solution.
  • the product was obtained from slightly aqueous acetone or isopropanol. It was very slightly hygroscopic.
  • the mixture was titrated to pH 7.2 with IM KOH solution, the layers separated and the aqueous layer evaporated to near dryness, diluted slowly with isopropanol-acetone and cooled to 2-3 C when crystallisation occurred. The compound was filtered off, washed with acetone and dried in vacuo, to yield 1.7 g of the potassium salt.
  • the compound was further purified by solution in a small volume of water and treatment with activated charcoal. After filtration to remove charcoal the filtrate was diluted with acetone or isopropanol; after seeding, scratching and cooling the pure colourless potassium salt crystallised and was collected, washed with acetone and dried, to yield 1.1 g.
  • Benzyl-9-azido-9-deoxyclavulanate (2 g) was dissolved in tetrahydrofuran (40 ml)/water (20 ml) and the solution ice cooled and stirred vigorously. Zinc powder (5 g) was added in small quantities over 11 ⁇ 2 hours, while maintaining the pH of the solution between 3 and 4 by dropwise addition of 2N HCl. When benzyl 9-azido-9-deoxyclavulanate could no longer be detected in the solution (silica tlc, eluent ethyl acetate/petroleum ether 1:2), the pH was adjusted to 6 with 1N aqueous sodium bicarbonate and the solution filtered.
  • the filtrate was saturated with NaCl and extracted with ethyl acetate (3 x 30 ml).
  • the combined ethyl acetate extracts were dried over MgSO 4 and evaporated under reduced pressure to ca. 50 ml to provide a solution containing benzyl 9-amino-9-deoxyclavulanate.
  • This solution was treated with acetic anhydride (1.0 ml) and pyridine (0.52 ml), stirred 1 hour at room temperature, washed with 0.1 N HCl (50 ml), 1N aqueous sodium bicarbonate solution (50 ml) and water (50 ml), dried over MgS0 4 and evaporated under reduced pressure.
  • Benzyl 9-acetamido-9-deoxyclavulanate (0.40 g,1.21 mmole) was dissolved in dry dichloromethane (7ml) and ice cooled. This solution was treated with pyridine (0.195 ml, 2.42 mmole) and then with a 12.5% solution of phosgene in toluene (1.48 ml). After stirring at room temperature for 80 minutes, the solution was evaporated under reduced pressure and the residue quickly dissolved in dry dichloromethane (10 ml). This solution was ice cooled, treated with tetramethylguanidinium azide (0.47 g, 3.02 mmole) and then stirred at room temperature for 30 minutes.
  • Benzyl 9-acetmido-9-deoxyclavulanate (0.10 g, 0.303 mmole) was dissolved in dry dichloromethane (5 ml) and ice cooled. The solution was treated with pyridine (0.081 ml) and phosphorus pentachloride (0.066 g, 0.318 mmole) and stirred 30 minutes at 0 - 5°C. Tetramethylguanidinium azide (0.156 g, 1 mmole) was then added and the solution stirred a further 30 minutes at O - 5°C, washed with 0.5 NHC1(10 ml), dried over MgSO 4 and evaporated under reduced pressure. The residue was chromatographed as in example 23 to provide benzyl 9-(5'-methyltetrazol-1'-yl)-9-deoxyclavulanate (0.08 g), identical to the product of example 23.
  • Benzyl 9-(5-methyltetrazol-1-yl)-9-deoxyclavulanate (0.28 g, 0.79 mmole) was dissolved in distilled tetrahydrofuran (15 ml), treated with 10% palladium/charcoal (90 mg) and hydrogenolysed for 30 minutes at atmospheric pressure. The suspension was filtered through celite and the filtrate evaporated under reduced pressure to 2 ml. Water (5 ml) was added and this solution was brought to pH 7 by dropwise addition of 0.5N aqueous KOH, washed with ethyl acetate (2 x 10 ml), concentrated to ca. 5 ml under reduced pressure and freeze dried.
  • Benzyl 9-benzamido-9-deoxyclavulanate (0.25 g, 0.64 mmole) was dissolved in dry dichloromethane (15 ml) and ice cooled. The solution was treated with pyridine (.52ml) and then with a 12.5% solution of phosgene in toluene (5.6 ml). This mixture was stirred at room temperature for 18 hours, evaporated under reduced pressure and the residue quickly redissolved in dry dichloromethane (15 ml). This solution was ice cooled, stirred and treated with tetramethylguanidinium azide (0.203 g, 1.3 mmole).
  • Benzyl 9-(5'-phenyltetrazol-1'-yl)-9-deoxyclavulanate (0.18g, 0.433 mmole) was dissolved in distilled tetrahydrofuran (10 ml), treated with 10% palladium/charcoal (50 mg) and hydrogenolysed for 30 minutes at atmospheric pressure.
  • tert-Butyldiphenylsilyl 9-(tetrazol-2-yl)-9-deoxyclavulanate (30 mg) was dissolved in distilled tetrahydrofuran (2.7 ml), ice cooled and treated with 1N aqueous hydrochloric acid (0.3 ml). The solution was stirred at room temperature for 45 minutes and saturated brine (10 ml) was added. The resulting mixture was extracted with ethyl acetate (2 x 10 ml) and the ethyl acetate dried over MgSO 4 and evaporated under reduced pressure.
  • Trii sopropylsilylclavulanate (1.20 g, 3.38 mmole), tetrazole (0.5 g, 7.15 mmole) and triphenylphosphine (1.06 g, 4.05 mmole) were dissolved in distilled tetrahydrofuran (20 ml), cooled to -10°C and treated with diethylazodicarboxylate (0.665 ml, 4.05 mmole). The mixture was stirred for 15 minutes while warming to about 10°C and evaporated under reduced pressure. The residue was chromatographed on silica, eluting with ethyl acetate/hexane 1:2.
  • Triisopropylsilyl 9-(tetrazol-2-yl)-9-deoxyclavulanate (90 mg) was dissolved in distilled tetrahydrofuran (9 ml), ice cooled and treated with 1N aqueous hydrochloric acid (1 ml). The solution was stirred 25 minutes at 0 - 5°C and saturated brine (20 ml) added. The resulting mixture was extracted with ethyl acetate (2 x 30 ml) and the ethyl acetate dried over MgS0 4 and evaporated. The residue was taken up in distilled tetrahydrofuran (5 ml) and water (5 ml) and the solution brought to pH 7 with 1N LiOH solution.
  • the benzyl ester (0.237 g) in redistilled tetrahydrofuran (20 ml) was hydrogenated over 10% palladised charcoal (monitored by tlc). After 45 minutes the catalyst was filtered off, the filtrate cooled to 0 C and diluted with water (40 ml). The solution was adjusted to pH 7 with 1M potassiumhydroxide solution and evaporated to dryness to yield 0.2 g of crude potassium salt. The product was chromatographed on silica gel using 2:1:1 butanol-ethanol- water as elution solvent.
  • Example 34 The product from Example 34 (0.45 g) in tetrahydrofuran was hydrogenated over 10% palladised charcoal (0.2 g). When the reaction was complete, the catalyst was removed by filtration, water added and the mixture titrated to pH 7.0 with 1M LiOH.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP81305564A 1980-12-09 1981-11-25 Dérivés de l'acide clavulanique, leur préparation et leur application Expired EP0053893B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8039447 1980-12-09
GB8039447 1980-12-09
GB8118110 1981-06-12
GB8118110 1981-06-12

Publications (2)

Publication Number Publication Date
EP0053893A1 true EP0053893A1 (fr) 1982-06-16
EP0053893B1 EP0053893B1 (fr) 1985-03-20

Family

ID=26277788

Family Applications (1)

Application Number Title Priority Date Filing Date
EP81305564A Expired EP0053893B1 (fr) 1980-12-09 1981-11-25 Dérivés de l'acide clavulanique, leur préparation et leur application

Country Status (10)

Country Link
US (3) US4544549A (fr)
EP (1) EP0053893B1 (fr)
AU (1) AU7836681A (fr)
CA (1) CA1175052A (fr)
DE (1) DE3169452D1 (fr)
ES (4) ES507822A0 (fr)
GR (1) GR76964B (fr)
IE (1) IE52228B1 (fr)
NZ (1) NZ199061A (fr)
PT (1) PT74092B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984003092A1 (fr) * 1983-02-10 1984-08-16 Beecham Group Plc Derives de clavame

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305837D0 (en) * 1993-03-20 1993-05-05 Smithkline Beecham Plc Novel compounds
US6979735B1 (en) * 1999-04-01 2005-12-27 Dsm N.V. Agglomerates by crystallization

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2725203A1 (de) * 1976-06-04 1977-12-22 Glaxo Lab Ltd Neue clavamsaeurederivate und verfahren zu deren herstellung
EP0001516A1 (fr) * 1977-10-10 1979-04-18 Glaxo Group Limited Composés beta-lactames, procédés pour leur préparation, compositions pharmaceutiques les contenant et intermédiaires utilisés pour leur préparation

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR205682A1 (es) * 1970-06-11 1976-05-31 Philips Nv Metodo de produccion de ester (2-dimetilaminoetil) de acido (4-cloro-alfa - metilbenciliden) amino-oxiacetico y sus sales de adicion de acido formadas con acidos farmacologicamente aceptables
US4399142A (en) * 1973-05-03 1983-08-16 Smith Kline & French Laboratories Limited Pharmacologically active compounds
NZ177159A (en) * 1974-04-20 1978-03-06 Beecham Group Ltd Clavulanic acid, salts, esters and preparation thereof from streptomyces clavuligerus: pharmaceutical compositions
AU503489B2 (en) * 1975-10-13 1979-09-06 Beecham Group Limited Substituted aminodeoxy clavulanic acid
GB1561290A (en) * 1975-10-16 1980-02-20 Nyegaard & Co As Pyrimid - 2 - ones
GB1515241A (en) * 1976-01-27 1978-06-21 Beecham Group Ltd Beta-lactam antibiotics
PT66071B (en) * 1976-01-31 1978-06-23 Beecham Group Ltd Clavulanic acid thioethers
BE858858A (fr) * 1976-10-16 1978-03-20 Fisons Ltd Composition de cromoglycate disodique
GB1599907A (en) * 1977-04-26 1981-10-07 Glaxo Lab Ltd Isoindolines
EP0007152A1 (fr) * 1978-04-28 1980-01-23 Beecham Group Plc Antibiotiques bêta-lactames, préparation et application
US4446146A (en) * 1978-07-26 1984-05-01 Beecham Group Limited β-Lactam containing compounds, their preparation and use
EP0007753B1 (fr) * 1978-08-02 1982-08-25 Beecham Group Plc Agents antibactériens de bêta-lactame, un procédé pour leur préparation et compositions pharmaceutiques les contenant
EP0008877B1 (fr) * 1978-09-09 1983-10-26 Beecham Group Plc Dérivés d'acide clavulanique, un procédé pour leur préparation et leurs compositions
US4405596A (en) * 1978-10-16 1983-09-20 Helbig Joachim W Pharmaceutical preparations for and treatment procedures involving increasing plasma bicarbonate level
DE2849646A1 (de) * 1978-11-16 1980-06-04 Hoechst Ag Thienylbenzoesaeurederivate und verfahren zu ihrer herstellung
CA1152517A (fr) * 1979-06-29 1983-08-23 Ian H. Coates Composes heterocycliques, procede de preparation et application
FI75578C (fi) * 1979-07-25 1988-07-11 Ciba Geigy Ag Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider.
AU6119980A (en) * 1979-08-09 1981-02-12 Glaxo Group Limited Benzoxocin derivatives
US4402949A (en) * 1979-11-12 1983-09-06 Sandoz Ltd. Stable solutions of hydrogenated ergotalkaloids
US4315935A (en) * 1980-04-14 1982-02-16 Smithkline Corporation N,N'-Bis[substituted-1,2,3,4-tetrahydroisoquinolinolyl]disulfonylimides and antiallergic compositions and method of use
US4317826A (en) * 1980-05-27 1982-03-02 Smithkline Corporation N,N'-Bis[substituted-1,2,3,4 tetrahydroisoquinolyl]disulfonylimides and antiallergic compositions and method of use
IT1150955B (it) * 1980-06-06 1986-12-17 Lepetit Spa Derivati 3h-naft(1.2-d)-imidazolici il procedimento per la loro preparazione, il loro uso come agenti antiinfiammatori e le composizioni farmaceutiche che li contengono
EP0043197A1 (fr) * 1980-07-02 1982-01-06 Beecham Group Plc Antibiotique bêta-lactame, préparation et application
US4321254A (en) * 1980-09-26 1982-03-23 Smithkline Corporation Antiallergic imidodisulfamides
US4385047A (en) * 1981-01-05 1983-05-24 Smithkline Beckman Corporation Antiallergic imidodisulfamides
US4350685A (en) * 1981-02-06 1982-09-21 Smithkline Corporation Antiallergic imidodisulfamides
US4341786A (en) * 1981-03-02 1982-07-27 Smithkline Corporation Pharmaceutical compositions and method of producing central alpha1 agonist activity utilizing octahydrobenzo[f]quinoline compounds
FR2502153A1 (fr) * 1981-03-19 1982-09-24 Rech Pharmaceutiq Medicale Acides (2-oxo-3-tetrahydrothienylcarbamoyl)-alkylthio) acetiques, leurs sels et leurs esters, leur procede de preparation et les compositions pharmaceutiques en contenant
US4401665A (en) * 1981-04-14 1983-08-30 Bristol-Myers Company Sleep-aid composition containing an analgesic and diphenhydramine dihydrogencitrate, and method of use
US4402976A (en) * 1981-04-24 1983-09-06 E. R. Squibb & Sons, Inc. Method for treating glaucoma with systemic nadolol compositions
US4402974A (en) * 1981-06-23 1983-09-06 American Hospital Supply Corporation Method for treating glaucoma by the topical administration of selectively metabolized beta-blocking agents
US4352809A (en) * 1981-09-04 1982-10-05 Smithkline Corporation Method of producing alpha2 antagonism
US4406898A (en) * 1981-09-08 1983-09-27 Eli Lilly And Company Oxazole and oxadiazole cephalosporins
US4396620A (en) * 1981-09-08 1983-08-02 Eli Lilly And Company Cephalosporin quinolinium betaines
US4396619A (en) * 1981-09-08 1983-08-02 Eli Lilly And Company Cephalosporin betaines
US4382932A (en) * 1981-09-08 1983-05-10 Eli Lilly And Company Isoquinolinium substituted cephalosporins
US4401668A (en) * 1981-10-02 1983-08-30 Eli Lilly And Company Pyrazinium substituted cephalosporins
US4388316A (en) * 1981-10-02 1983-06-14 Eli Lilly And Company Amino-substituted oxazole, oxadiazole and isoxazole-substituted cephalosporins
US4402955A (en) * 1981-10-02 1983-09-06 Eli Lilly And Company Dioximino cephalosporin antibiotics
US4379787A (en) * 1981-10-02 1983-04-12 Eli Lilly And Company Oximino-substituted cephalosporin compounds
US4406899A (en) * 1982-03-04 1983-09-27 Bristol-Myers Company Cephalosporins
US4397845A (en) * 1982-05-19 1983-08-09 The Upjohn Company Lincomycin 3-(5'-adenylate) as anesthetic

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2725203A1 (de) * 1976-06-04 1977-12-22 Glaxo Lab Ltd Neue clavamsaeurederivate und verfahren zu deren herstellung
EP0001516A1 (fr) * 1977-10-10 1979-04-18 Glaxo Group Limited Composés beta-lactames, procédés pour leur préparation, compositions pharmaceutiques les contenant et intermédiaires utilisés pour leur préparation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984003092A1 (fr) * 1983-02-10 1984-08-16 Beecham Group Plc Derives de clavame

Also Published As

Publication number Publication date
PT74092B (en) 1983-05-23
IE52228B1 (en) 1987-08-19
ES8307251A1 (es) 1983-06-16
US4645671A (en) 1987-02-24
ES507822A0 (es) 1983-06-16
NZ199061A (en) 1984-10-19
ES516334A0 (es) 1984-05-16
US4544549A (en) 1985-10-01
CA1175052A (fr) 1984-09-25
ES520675A0 (es) 1984-05-16
ES8405015A1 (es) 1984-05-16
ES516333A0 (es) 1984-05-16
PT74092A (en) 1982-01-01
GR76964B (fr) 1984-09-04
ES8405014A1 (es) 1984-05-16
ES8405016A1 (es) 1984-05-16
DE3169452D1 (en) 1985-04-25
AU7836681A (en) 1982-06-17
EP0053893B1 (fr) 1985-03-20
US4584291A (en) 1986-04-22
IE812881L (en) 1982-06-09

Similar Documents

Publication Publication Date Title
US4382084A (en) Antibiotics
US4544549A (en) Derivatives of clavulanic acid, their preparation and their use
IE45559B1 (en) Lactam antibiotics
EP0055062B1 (fr) Composés contenant des bêta-lactames
US4258050A (en) Antibacterial agents
US4548815A (en) Antibacterial agents
GB2090247A (en) Tetrazolyl derivatives of clavulanic acid
US4571392A (en) 6-Substituted derivatives of clavulanic acid
EP0050932B1 (fr) Composés thérapeutiques contenant des bêta-lactames
EP0112685B1 (fr) Composés contenant des bêta-lactames
EP0167050A1 (fr) Clavulanates, leur préparation et application ainsi que leurs produits intermédiaires
EP0002319B1 (fr) Dérivés de l'acide clavulanique, procédé pour leur préparation et compositions les contenant
EP0018203B1 (fr) Dérivés de l'acide clavulanique, leur préparation et leur application utilisation dans des compositions pharmaceutiques
EP0023093B1 (fr) Dérivés de l'acide pénicillanique, leur préparation et leurs compositions pharmaceutiques avec une pénicilline ou céphalosporine
EP0003254B1 (fr) Dérivés de l'acide clavulanique, procédé pour leur préparation et compositions les contenant
EP0067518B1 (fr) Composés de bêta-lactame modifiés
EP0068609A1 (fr) Dérivés de l'acide clavulanique, un procédé pour leur préparation et leur application
EP0046349A1 (fr) Dérivés de l'acide clavulanique, leur préparation et application
WO1984003092A1 (fr) Derives de clavame
EP0080285A1 (fr) Composés thérapeutiques contenant des bêta-lactames
EP0024372A1 (fr) Dérivés de l'acide clavulanique, leur préparation et compositions pharmaceutiques les contenant
GB2052981A (en) Penicillanic acid derivatives as beta -lactamase inhibitors
EP0080284A1 (fr) Dérivés de l'acide clavulanique, procédés pour leur préparation et leur application
EP0062407A1 (fr) Composés thérapeutiques à cycle bête-lactame
EP0068715A1 (fr) Agents antibactériens dérivés de bêta-lactame, leurs préparation et application

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE CH DE FR IT LU NL SE

17P Request for examination filed

Effective date: 19820722

ITF It: translation for a ep patent filed

Owner name: SOCIETA' ITALIANA BREVETTI S.P.A.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): BE CH DE FR IT LI LU NL SE

REF Corresponds to:

Ref document number: 3169452

Country of ref document: DE

Date of ref document: 19850425

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19851130

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19861126

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19911107

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19911127

Year of fee payment: 11

ITTA It: last paid annual fee
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19911130

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19911230

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19920107

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19921130

Ref country code: CH

Effective date: 19921130

Ref country code: BE

Effective date: 19921130

BERE Be: lapsed

Owner name: BEECHAM GROUP P.L.C.

Effective date: 19921130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19930601

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19930730

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19930803

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

EUG Se: european patent has lapsed

Ref document number: 81305564.7

Effective date: 19870901